A new single-cell technology is giving scientists their clearest view yet of immune cell behavior-capturing not just genetic intent but real-time activity.

Post hoc analyses of pivotal MITIGATE trial show broad efficacy across patient subgroups with differing organ involvement and clinical characteristics.

St. Jude Children's Research Hospital scientists have discovered how tumors disable immune "gatekeeper" cells that alert the ...

St. Jude Children's Research Hospital scientists have discovered how tumors disable immune "gatekeeper" cells that alert the rest of the immune system to the presence of cancer - and how restoring ...

Using a variety of laboratory and animal models, the team found that cysteine fuels the production of the antioxidant ...

“Interestingly, BIRC5 and MCL-1 have both been reported to be over-expressed and strongly correlated with progression and ...

CD19-targeted CAR T-cell therapy shows a 65% response rate in Richter transformation, with median progression-free survival of 8 months and overall survival of 14.4 months. Early response and age are ...

Stem cells are the body's ultimate shape-shifters, sustaining tissues by balancing two competing demands: maintaining their ...

Olvi-Vec shows potential in treating advanced lung cancer, demonstrating tumor shrinkage and disease control in patients unresponsive to platinum-based treatments. The investigational therapy is an ...

An engineered viral protein enhanced the anticancer function of T cells in mice, suggesting a new strategy to improve immunotherapy. Courtney and his team sought to exploit this property of TIP to ...